Opinion|Videos|August 7, 2024
Additional Data and Key Takeaways in CLL/SLL from EHA 2024
Author(s)Mazyar Shadman, MD, MPH
Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Are there any noteworthy key takeaways or additional data updates on CLL/SLL treatments discussed at EHA 2024 that you wish to share?
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5